Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lecanemab: Appropriate Use Recommendations
J Cummings, L Apostolova, G D Rabinovici, et al.
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 383

Showing 1-25 of 383 citing articles:

2024 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3708-3821
Open Access | Times Cited: 628
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 619
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Harald Hampel, Aya Elhage, Min Cho, et al.
Brain (2023) Vol. 146, Iss. 11, pp. 4414-4424
Open Access | Times Cited: 140
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Li‐Kai Huang, Yi‐Chun Kuan, Ho-Wei Lin, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 137
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Davis Cammann, et al.
BioDrugs (2023) Vol. 38, Iss. 1, pp. 5-22
Open Access | Times Cited: 132
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 122
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Sebastian Palmqvist, Pontus Tideman, Niklas Mattsson, et al.
JAMA (2024) Vol. 332, Iss. 15, pp. 1245-1245
Closed Access | Times Cited: 89
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock, Jeremiah A. Aakre, Anna Castillo, et al.
Neurology (2023) Vol. 101, Iss. 19
Open Access | Times Cited: 85
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 76
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
Linus Jönsson, Anders Wimo, Ron Handels, et al.
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100657-100657
Open Access | Times Cited: 73
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
Vijay K. Ramanan, Gregory S. Day
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 50
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 47
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 46
Dementia Prevention and Treatment
David B. Reuben, Sarah Kremen, Donovan T. Maust
JAMA Internal Medicine (2024) Vol. 184, Iss. 5, pp. 563-563
Open Access | Times Cited: 44
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Gil D. Rabinovici, Renaud La Joie
JAMA (2023) Vol. 330, Iss. 6, pp. 507-507
Closed Access | Times Cited: 43
Multifaceted roles of APOE in Alzheimer disease
Rosemary J. Jackson, Bradley T. Hyman, Alberto Serrano‐Pozo
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 457-474
Closed Access | Times Cited: 39
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Sarah J. Doran, Russell P. Sawyer
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 29
Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Joseph Therriault, Nicholas J. Ashton, Ilaria Pola, et al.
EBioMedicine (2024) Vol. 102, pp. 105046-105046
Open Access | Times Cited: 26
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8074-8096
Open Access | Times Cited: 26
AI-based differential diagnosis of dementia etiologies on multimodal data
Chonghua Xue, Sahana S. Kowshik, Diala Lteif, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2977-2989
Open Access | Times Cited: 23
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah E. Abdallah
RSC Advances (2024) Vol. 14, Iss. 16, pp. 11057-11088
Open Access | Times Cited: 20
The advent of Alzheimer treatments will change the trajectory of human aging
Dennis J. Selkoe
Nature Aging (2024) Vol. 4, Iss. 4, pp. 453-463
Closed Access | Times Cited: 19
Sex-dependent APOE4 neutrophil–microglia interactions drive cognitive impairment in Alzheimer’s disease
Neta Rosenzweig, Kilian Kleemann, Thomas M. Rust, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2990-3003
Closed Access | Times Cited: 18
Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
A. Laurell, Ashwin Venkataraman, Tatjana Schmidt, et al.
The British Journal of Psychiatry (2024) Vol. 224, Iss. 6, pp. 198-204
Open Access | Times Cited: 17
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Yoshiki Niimi, Shorena Janelidze, Kenichiro Sato, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top